Perceptive Advisors’s Immunic IMUX Stock Holding History

Perceptive Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-375	Closed	-$454K	–	140
2018 Q1	$454K	Buy	+375	New	+$861K	0.01%	126
2015 Q3	–	Sell	-750	Closed	-$6.33M	–	169
2015 Q2	$6.33M	Buy	+750	New	+$7.16M	0.38%	58

Other funds holding IMUX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Perceptive Advisors's IMUX Position: Q3 2018 in Review

Perceptive Advisors sold out of Immunic (IMUX) in Q3 2018, closing a stake of 375 shares — an estimated $405K sold.

Perceptive Advisors first reported a position in IMUX in Q1 2016 and held it in 2 quarters. The position peaked at $405K in Q2 2018. 54 funds tracked by Wall St. Rank hold IMUX as of Q3 2018.

Perceptive Advisors reported no remaining Immunic position as of Q3 2018 after selling out during the quarter.
Perceptive Advisors sold 375 Immunic shares in Q3 2018, an estimated $405K.
Perceptive Advisors first reported a position in Immunic in Q1 2016 and held it in 2 quarters.
Perceptive Advisors's Immunic position peaked at $405K in Q2 2018.
54 funds tracked by Wall St. Rank held Immunic as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.